WHEN STAT ISN’T FAST ENOUGH

Norepinephrine Bitartrate in 5% Dextrose Injection

Indication

Norepinephrine Bitartrate in Dextrose Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension.
Please read the accompanying full Indication and Important Risk Information and full Prescribing Information

Premix from Baxter: Norepinephrine Bitartrate in 5% Dextrose Injection

A Premix from Baxter:
Norepinephrine Bitartrate in 5% Dextrose Injection

The first and only FDA-approved, ready-to-use Premix Norepinephrine

Consistent concentration to help minimize risk of medication errors due to compounding1,2

Reduced wait time for drug administration as compared to compounding 

Room temperature storage, making it available near the point of care

See detailed storage information below.

Distinctly labeled, barcoded product bag, with an overwrap that differentiates product strength (concentration)

Patient Safety

Reduction of Medication Errors

Premix Norepinephrine provides an accurately prepared concentration in a barcoded bag to help minimize risk of compounding errors that may be heightened in urgent situations. 1,2

Compliance

Premix Norepinephrine delivers the safety and reliability of compliance with ISMP and ASHP guidelines in a shelf-stable, ready-to-use formulation.1,2

Distinct Labeling

Premix Norepinephrine has a distinctly labeled bag, with a light-shielding overwrap that also differentiates product strength (concentration).

Care and Efficiency

Grab-and-go

Make every second count with a ready-to-use IV medication that helps protect your patients while improving efficiency.

Store Closer to the Patient

Premix Norepinephrine allows for the storage of norepinephrine on the floor and in your ADC, right where you need it when you need it, with reduced concern for waste.3

Operational Efficiency

Premix Norepinephrine may free up your pharmacy staff to focus on compounding other critical high-alert medications.

On-Demand Availability

90-day room temperature or refrigerated stability until manufacturer expiration date (21-month refrigerated shelf-life) puts Premix Norepinephrine at the point of care. 

See detailed storage information below.

Premix Norepinephrine from Baxter:

Premix Norepinephrine from Baxter has distinctly labeled packages with light-shielding overpouch

Premix Norepinephrine labels include bold colors on the light-shielding overwrap, tall man lettering, and barcodes to help reduce the potential of medication errors.2

Order Premix Norepinephrine Now

Baxter Premix Norepinephrine: Specifications

Baxter Premix Norepinephrine Product Specification

Norepinephrine Bitartrate in 5% Dextrose Injection

Important Risk Information

Indication

Norepinephrine Bitartrate in Dextrose Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension.

Contraindications

• None

Warnings and Precautions

Tissue Ischemia: Administration of Norepinephrine Bitartrate in Dextrose Injection to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating Norepinephrine Bitartrate in Dextrose Injection. Avoid use in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction.
Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients.
Extravasation of Norepinephrine Bitartrate in Dextrose Injection may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation. Avoid administration into the veins in the leg in elderly patients.
Emergency Treatment of Extravasation: Infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults.
Hypotension after Abrupt Discontinuation: Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the Norepinephrine Bitartrate in Dextrose Injection infusion rate while expanding blood volume with intravenous fluids.
Cardiac Arrhythmias: Norepinephrine Bitartrate in Dextrose Injection elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias.
• Most common adverse reactions are hypertension and bradycardia.
Drug Interactions:
Co-administration of Norepinephrine Bitartrate in Dextrose Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) or with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.
Anti-diabetics: Norepinephrine Bitartrate in Dextrose Injection can decrease insulin sensitivity and raise blood glucose.
Concomitant use of Norepinephrine Bitartrate in Dextrose Injection with halogenated anesthetics (e.g., cyclopropane, desflurane, enflurane, isoflurane, and sevoflurane) may lead to ventricular tachycardia or ventricular fibrillation. Monitor cardiac rhythm in patients receiving concomitant halogenated anesthetics.
• Elderly patients may be at greater risk of developing adverse reactions.

Please click here for Norepinephrine Bitartrate in 5% Dextrose Injection full Prescribing Information.

Indications for Use

The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used for the controlled administration of fluids. These may include pharmaceutical drugs, blood, blood products. The intended routes of administration consist of the following clinically accepted routes: intravenous, arterial, subcutaneous or epidural.
The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used in conjunction with legally marketed and compatible intravenous administration sets and medications provided by the user.
The Spectrum IQ Infusion System with Dose IQ Safety Software is suitable for a variety of patient care environments such as, but not limited to, hospitals and outpatient care areas.
Rx Only. For safe and proper use of these devices, please refer to the complete instructions for use or appropriate operator’s manual.

Select Important Risk Information

WARNINGS AND PRECAUTIONS
Tissue Ischemia: Administration of Norepinephrine Bitartrate in Dextrose Injection to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating Norepinephrine Bitartrate in Dextrose Injection. Avoid use in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction.

Please click the Learn More button for additional Important Risk Information and accompanying Prescribing Information

Learn More